Adicet Bio
ACET
49 hedge funds and large institutions have $43.7M invested in Adicet Bio in 2026 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 11 closing their positions.
12,333% more call options, than puts
Call options by funds: $373K | Put options by funds: $3K
62.41% more ownership
Funds ownership: 4.39% → 66.8% (+62%)
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
9% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 11
0% more funds holding
Funds holding: 49 → 49 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
23% less capital invested
Capital invested by funds: $56.6M → $43.7M (-$12.9M)
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$2.05M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$1.75M |
| 3 |
TI
Trexquant Investment
Stamford,
Connecticut
|
+$327K |
| 4 |
Jane Street
New York
|
+$278K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$259K |
Top Sellers
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$2.33M |
| 2 |
Goldman Sachs
New York
|
-$1.97M |
| 3 |
Two Sigma Investments
New York
|
-$761K |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$560K |
| 5 |
LM
Luminus Management
Houston,
Texas
|
-$501K |
ACET Hedge Fund Activity: Q1 2026 in Review
49 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q1 2026, worth a combined $43.7M — down 23% from $56.6M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ACET positions and 11 closed out — a net gain of 1 holder — while 12 added to existing stakes and 8 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $2.05M. The largest seller was Woodline Partners, cutting an estimated $2.33M.
- 49 institutional investors held Adicet Bio (ACET) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $43.7M of Adicet Bio stock for Q1 2026, down 23% quarter-over-quarter.
- 12 funds opened new Adicet Bio positions in Q1 2026 and 11 closed out, a net change of +1 holder.
- The largest Adicet Bio buyer in Q1 2026 was Citadel Advisors, an estimated $2.05M added.
- The largest Adicet Bio seller in Q1 2026 was Woodline Partners, an estimated $2.33M sold.
Based on aggregated 13F filings for Q1 2026.